Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

Video

In Partnership With:

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

MCL is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma, says Karmali. The majority of patients who are diagnosed with MCL are older. Additionally, these patients may have comorbidities or be medically unfit, thereby limiting their ability to undergo intensive chemoimmunotherapy with or without an autologous stem cell transplant (ASCT).

As such, these patients may have poorer outcomes, says Karmali. To that end, researchers conducted an analysis that evaluated the practice patterns and survival outcomes of patients 65 years of age or older with newly diagnosed MCL. The results were presented during the 2020 ASCO Virtual Scientific Program.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,